Riyadh Air Partners with Loyalty Juggernaut to Launch a Next-Generation Digital Loyalty Program
, May 7, 2025 /CNW/ -- Riyadh Air, the new national carrier of Saudi Arabia, and Loyalty Juggernaut, Inc. (LJI), an innovation leader in loyalty technology, announced today a strategic partnership to power Riyadh Air's next-generation digital loyalty program, during the Arabian Travel Market in Dubai, UAE.
As Riyadh Air prepares to redefine travel experiences for a new era, the airline is building a loyalty program that is as modern, dynamic, and digitally native as the brand itself. Powered by Loyalty Juggernaut's cloud-native GRAVTY ® platform, Riyadh Air's loyalty program will deliver a fully personalized, seamless, and rewarding experience for travelers worldwide.
"At Riyadh Air, we are committed to setting a new standard in customer experience," said Vincent Coste, Chief Commercial Officer of Riyadh Air. "Loyalty Juggernaut's cutting-edge GRAVTY ® platform allows us to create a digital-first loyalty program that matches the ambition, innovation, and scale of Riyadh Air. Together, we are shaping the future of travel loyalty."
He added, "the program will feature real-time engagement, AI-driven personalization, expanded partnerships, dynamic earn and redemption opportunities, and a seamless mobile-first experience—redefining traditional loyalty for a new generation of travelers."
Designed for scale and innovation, the GRAVTY ® platform's modular, API-first architecture ensures rapid deployment, future-proof scalability, and effortless integration with Riyadh Air's broader digital ecosystem.
"We are honored to partner with Riyadh Air in this landmark initiative," said Shyam Shah, CEO of Loyalty Juggernaut. "Our mission is to elevate loyalty into a strategic growth engine. GRAVTY ® 's nextgen capabilities will enable Riyadh Air to deliver extraordinary value to its guests and partners, setting a bold new benchmark in airline loyalty."
The new loyalty program is expected to launch ahead of Riyadh Air's inaugural flights and will be a core pillar of the airline's broader customer engagement and growth strategy.
This partnership represents a shared vision: to build a loyalty experience that goes beyond points and miles—to create lasting emotional engagement with travelers at every touchpoint.
About Riyadh Air
Riyadh Air is Saudi Arabia's new world-class airline, launched to connect the Kingdom to more than 100 destinations worldwide. Headquartered in Riyadh and backed by the Public Investment Fund (PIF), Riyadh Air is committed to delivering an exceptional, technology-driven travel experience that reflects the future of aviation.
About Loyalty Juggernaut
Loyalty Juggernaut (LJI) is a leading B2B SaaS provider of next-generation loyalty and customer engagement solutions. LJI's flagship GRAVTY ® platform powers some of the world's most innovative loyalty ecosystems, enabling enterprises to elevate loyalty into a measurable, strategic growth engine. Headquartered in Palo Alto, California, LJI serves leading brands across industries, including airlines, retail, hospitality, and financial services.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
SGS Acquires H2Safety to Optimize Emergency Management and Operational Safety for North American Industrial Sectors
CALGARY, AB, June 4, 2025 /CNW/ - SGS, the world's leading testing, inspection and certification company announces the acquisition of H 2 Safety Services Inc. (H 2 Safety), a North American market leader in emergency response management, Health Safety and Environment (HSE), training and emergency software services. Founded in 2004, H 2 Safety serves a wide range of industrial sectors including oil and gas, mining, transportation, utilities, renewables and government. With a unique focus on public consultation and regulatory compliance, H 2 Safety also excels in Indigenous relations and government relations. "Our approach to safeguarding critical infrastructure, communities, employees and natural environments is rooted in building authentic relationships and addressing community concerns transparently," said James Harasen, CEO and Chairman of H 2 Safety. "We are excited about joining SGS to expand our emergency management footprint while also leveraging SGS's proven expertise in delivering comprehensive HSE solutions across various industries." H 2 Safety's H2CommandCentre® platform is a robust emergency management application that empowers organizations with rapid and holistic incident management response capabilities. It activates emergency response teams including GIS and ICS experts, delivers rapid notifications, offers real-time check-ins, uses real-time maps to identify hazard zones while also generating lists of critical residents and stakeholders. With over 15,000 users, the platform is supporting organizations with achieving their operational safety objectives and business continuity, while also protecting people and the environment. "Operational integrity is at the core of SGS's corporate culture, since our customers entrust us with their quality assurance and operational fluidity needs in a wide range of industrial environments. Whether it's delivering inspections to monitor the integrity of oil pipelines or deterring wildlife from landing in hazardous substances, HSE is at the core of what we do. We also have a strong HSE record within our own operations, so we really walk the talk when it comes to protecting assets, employees and the environment," said Patrick Beck, Head of Industrial Services at SGS in North America. H 2 Safety contributes to achieving SGS's Strategy 27, which includes responding to megatrends driving growth in the TIC industry. One of these megatrends is innovation in digital capabilities and new technologies. Organizations in the industrial sector are investing more in digital transformation solutions to remain competitive and to increase market share. An end-to-end emergency management platform serves as a powerful digital tool to strengthen digital transformation when it comes to operational safety and compliance. Another megatrend driving growth in the TIC industry is ESG regulation and societal expectations. Optimizing HSE and emergency management, with a focus on Indigenous and community relations, positively contributes to achieving corporate environmental and social development objectives. With this acquisition, SGS is also building towards achieving the company's objective of doubling North American sales between 2023 to 2027. For media inquiries, please contact: ABOUT SGS SGS is the world's leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of 99,500 dedicated professionals. With over 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability. Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and trusted specialized brands, including Brightsight, Bluesign, Maine Pointe and Nutrasource. SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN:SW).
Toronto Star
6 hours ago
- Toronto Star
Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) — Check-Cap Ltd. (NASDAQ: CHEK) ('Check-Cap' or the 'Company'), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ('MediPharm Labs') and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time for Israeli Companies. ARTICLE CONTINUES BELOW Check-Cap is deeply disturbed that Mr. Taves would leverage the implied authority of his position as a senior BMO Executive to exploit the wartime circumstances currently affecting Israel, in order to knowingly spread false information aimed at harming Check-Cap's reputation, stock price, and business relationships. This conduct is not only unethical and unlawful - it is shameful. Specifically, MediPharm Labs's May 23, 2025 press release quoted Mr. Taves making what Check Cap believes to be demonstrably false statements about Check-Cap. Even more egregious, Mr. Taves, a financial executive who surely knows better, publicly disseminated his accusation of there being deficiencies in our public disclosures, without any actual factual basis whatsoever. Check-Cap believes that Mr. Taves is misusing his position of trust as a BMO Capital Markets Executive to intentionally issue these misleading statements during trading hours in order to manipulate and drive down Check-Cap's stock price, violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934. Check-Cap demands that MediPharm Labs and Mr. Taves immediately retract the defamatory press release, cease all related misleading communications, and publicly apologize for Mr. Taves disgraceful actions. The fact that Mr. Taves and MediPharm Labs have chosen to launch such deplorable and unfounded attacks on an Israeli company minutes before the start of Shabbat at a time of war is reprehensible. Check-Cap will vigorously defend its reputation and its rights against these highly unethical attempts at aspersion, market manipulation and interference in a public transaction. About Check-Cap Check-Cap (NASDAQ: CHEK) is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. C-Scan is an investigational device and is not available for sale in the United States. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Legal Notice Regarding Forward-Looking Statements This press release contains 'forward-looking statements' about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as 'may,' 'should,' 'could,' 'would,' 'predicts,' 'potential,' 'continue,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the 'Forward-looking Statements' and 'Risk Factors' in the Company's Annual Report on Form 20-F for the year endedDecember 31, 2023and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. info@
Cision Canada
7 hours ago
- Cision Canada
Fresenius Kabi Canada launches Iodixanol Injection 270 & 320 - the first and only generic to Visipaque® in Canada Français
Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol injection, Fresenius Kabi Canada is looking to expand into the contrast media space, with a commitment to bring more treatment options for patients requiring diagnostic imaging Iodixanol injection is approved for all indications of the reference product Visipaque ® and available immediately TORONTO, June 4, 2025 /CNW/ - Fresenius Kabi Canada, part of Fresenius group, announced the recent launch of Iodixanol Injection 270 and 320 for both the intravenous and intra-arterial administrations. Iodixanol Injection is a contrast agent with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. Health Canada's NOC approval of Iodixanol Injection 270 & 320 was granted on December 17, 2024, and is based on a thorough evaluation of a comprehensive data package demonstrating pharmaceutical equivalence to the reference drug Visipaque ®. With this approval, Fresenius Kabi is building its footprint in the contrast media space in Canada, following recent successful launches of contrast media products in the United States. Expanding a strong presence into the imaging agent space is a substantial cornerstone of Fresenius Kabi's Vision 2026 and the #FutureFresenius strategy. "Fresenius Kabi's Iodixanol Injection will be the first generic for injectable iodinated contrast media on the market in Canada," said Lee Fulford Sr. Marketing Manager, Specialty Pharma at Fresenius Kabi Canada. "With this launch we are committed to bringing value to Canadians, by lowering the cost as well as adding supply stability to a market that has had devastating shortages historically." In recent years global shortages of iodinated contrast media have led to Canadian healthcare agencies having to adopt strategies to mitigate shortages including selecting which patients would get contrast and reducing dosages where possible 1. Iodixanol injection was added in June 2022 to Health Canada's tier 3 drug shortage list. Tier 3 drug shortages are those likely to have the greatest potential impact to the Health Care system 2. "We are proud to be introducing an affordable alternative Iodixanol diagnostic option which will strengthen Canada's supply for this critical agent. This launch underscores our commitment to enhancing patient care through accessible therapies," said Martin Willner, General Manager, Fresenius Kabi Canada. About Fresenius Kabi: Fresenius Kabi, an operating company of Fresenius, specializes in clinical nutrition, medical technologies, and I.V. generics and fluids for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. About Iodixanol Injection Iodixanol injection is a non-ionic radiographic contrast medium with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. The lower osmolality of Iodixanol Injection (which is isotonic with blood) compared with conventional contrast media of similar iodine concentration can be expected to cause fewer and less severe osmolality-related disturbances, specifically, less pain, heat and burning sensation, upon injection 3. Fresenius Kabi's Iodixanol Injection is free of preservatives and comes in a polymer bottle. The container closure is not made with natural rubber latex. Fresenius Kabi Iodixanol Injection is currently available in six presentations for intra-arterial and intravenous procedures: 270 mg Iodine per mL: 100 mL polymer bottle 150 mL polymer bottle 320 mg Iodine per mL: 50 mL polymer bottle 100 mL polymer bottle 150 mL polymer bottle 200 mL polymer bottle For more information, please visit This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release. Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer, Dr. Marc-Alexander Mahl, Dr. Sang-Jin Pak Chairman of the Supervisory Board: Wolfgang Kirsch Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg - HRB 11654
